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Abstract 
C-H Activation/functionalisation and Flow Photochemical Heterocyclic Metamorphosis (FP-
HM) have been combined to synthesize a library of benzo[1,3]oxazepines, a rarely described 
heterocyclic family. This combined protocol allows a range of arylated products to be made 
from simple starting materials, and the cheap flow photochemical system has proven 
effective for rapid synthesis of gram-quantities of benzo[1,3]oxazepines. 
 
Introduction 
Within medicinal chemistry, the rapid generation of a library of products to investigate 
structure-activity relationships is vital for the synthesis of biologically-active molecules and 
investigation of a biological hypothesis.
1
 Significant additional diversity may be obtained by 
the late-stage functionalisation of advanced intermediates or complex natural products by 
exploiting existing functionality, whilst avoiding linear sequences and duplicated synthetic 
efforts.
2
 Two examples extensively used within medicinal chemistry include fluorination,
3
 to 
adjust a drug’s metabolic profile and properties, and C-H functionalisation,
4
 to introduce 
further complexity or add functionality. There are, however, draw-backs to this approach 
such as a lack of generality, functionalisation of only one site or even the formation 
intractable mixtures. An alternative less widely-investigated approach is exploitation of 
existing functionality by metamorphosing one heterocycle into another. Late-stage 
heterocyclic metamorphosis
5
 allows for significant transformation of a molecule’s physical 
properties, for example by altering the basicity, the dipole moment, and any hydrogen-bond 
affinity, as well as the geometrical configuration.
6
 The new molecular scaffold generated, 
and the subsequent library of derivatives, can be screened for biological activity alongside 
the original heterocycle, allowing for rapid data generation. One important consideration of 
late-stage functionalisation is that the method should be mild and chemo-selective and we 
believe that the Flow Photochemical Heterocyclic Metamorphosis (FP-HM) protocol detailed 
herein fulfils these requirements. 
 
We have directed our heterocyclic metamorphosis efforts towards transformations of the 
quinoline ring system, due to its importance in medicinal chemistry and as a privileged 
scaffold in the treatment of malaria (Scheme 1) and in anti-cancer drugs (Topotecan).
7
 
Kaneko,
8
 Buchardt
9
 and Albini
10
 have observed that quinoline N-oxides (3) can be 
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transformed into benzo[1,3]oxazepines (4), in variable yields when irradiated at >300 nm in 
non-hydrogen-bonding solvents. Benzo[1,3]oxazepines are an unusual heterocyclic system 
that have not been extensively reported
11
 and although formally anti-aromatic, the 2-aryl 
derivatives are easily isolated and purified. Importantly, the seven-membered [1,3]-
oxazepine ring leads to a slight geometrical distortion with respect to the quinoline ring 
system, and thus offers an interesting counterpoint to the parent quinoline for biological 
testing. 
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Scheme 1. Biologically important quinolines and the general scheme of this communication. 
Results and Discussion  
Commercially available quinoline (1a) was oxidised with sodium perborate in glacial AcOH 
(Scheme 2) to form the N-oxide derivative 2a.
12
 At this point we wished to develop a route 
to diversify this simple quinoline N-oxide by arylating the 2-position using C-H 
functionalisation. Whilst a range of methods for this transformation are known,
13
 we 
decided to use a slight variation of the Minisci-like radical arylation, reported by Horan, to 
form 3a.
13b
 Horan’s method uses diazonium salts derived in situ from anilines, and offers 
many benefits in terms of cost of materials, ready availability of aniline substrates, 
operational simplicity and facile purification. With a reliable route to the desired 2-aryl-
quinoline N-oxide (3a) in hand, we investigated the photochemical rearrangement of the 
quinoline N-oxide to the corresponding benzo[1,3]oxazepine 4a.  
 
N
O
H
1 eq. p-EtO2CC6H4NH2
1.2 eq. t-BuONO
MeCN, 40 °C
N H
2 eq. NaBO3·4H2O  
AcOH, 40 °C
2a
56%
N
hν (>300 nm)
PhMe
O
N
O
CO2Et
CO2Et
3a
39%
1a
Batch
4a
73%  
Scheme 2. Initial investigation towards benzo[1,3]oxazepine 4a. 
The UV-Vis spectrum of N-oxide 3a shows a significant band λmax (PhMe) = 346 nm, ε = 14.3 
M
-1
cm
-1
 (Figure 1, red), which maps onto the broad band with λmax = 335 nm of the 
commercially available 25 W Exo Terra UVB200 bulb (Figure 1, dotted blue). The use of such 
a 25 W bulb has many safety, cost and practical advantages over the powerful medium 
pressure mercury lamps that have been used in other systems
10a,d
 and permits facile scaling 
of the reactions when larger quantities of material are required due to its price and ready 
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availability. When a toluene solution of 3a (1 mg/mL; 3.5 mM) in a Pyrex™ test tube (20 mL) 
was irradiated for 18 hrs with the 25 W Exo Terra UVB200 bulb full conversion to 
benzo[1,3]oxazepine 4a was observed, along with some photochemical decomposition. 
Following flash column chromatography, 1,3-oxazepine 4a was isolated in 73% yield.  
 
 
Figure 1. UV-Vis of compound 3a overlaid with the output of the Exo Terra UVB200 bulb 
(toluene, unscaled). 
 
On the basis of this promising result, we attempted the transformation in our 
photochemical flow reactor, similar to those previously described.
14
 Accordingly, N-oxide 3a 
was dissolved in toluene (5 mM), and pumped using a Vapourtec E-Series peristaltic pump 
through a 10 mL reactor (PFA tubing: 1/16” OD, 0.5 mm ID) that was wrapped around a 25 
W Exo Terra UVB200 lamp, and the solution irradiated. No degassing of the solution was 
performed. By 
1
H-NMR we observed complete conversion into the desired 
benzo[1,3]oxazepine 4a (Scheme 3) in only 6 min and compound 4a was isolated in near 
quantitative yield. Following further experimentation, we extended the residence time in 
the reactor to 10 minutes to account for any operational or substrate variabilities. This 
significant improvement on the previous literature protocols in terms of yield, time and the 
continuous nature of the process makes scale-up facile. To prove the effectiveness of the 
procedure, we synthesized 1.9 g of 4a within a 17 h period, providing the product in 98% 
yield and excellent purity. For comparison, in 18 h the batch-mode could only process 
milligram quantities of material in small 20 mL Pyrex test tubes due to the poor irradiation 
profile of classical laboratory glassware, additionally, the purity profile of the crude 
1
H-NMR 
was significantly inferior. 
N
O
N
O
4a3a hν (>300 nm)PhMe, 10 min
0.005 M
Flow
CO2Et
CO2Et50 mg
2 g
97%
98%
 
Scheme 3. FP-HM performed on a gram-scale.  
 
With conditions for conversion of the parent quinolone to the N-oxide, C-H functionalisation 
and heterocycle metamorphosis in hand, our attention turned to investigating the scope of 
the reaction. Commercially available quinolines 1a and 1b were converted to the 
corresponding N-oxides (2a and 2b). C-H functionalisation was successful and provided 
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access to the requisite 2-arylquinoline N-oxides (3a-k), albeit in moderate yield. The main 
difficulties were found with sterically hindered anilines, for example in the case of 3f where 
only trace quantities were isolated, and 3k where the yield was 16% (Table 1). Pleasingly, 
when substrates 3a-k were subjected to the flow photochemical heterocyclic 
metamorphosis (FP-HM) conditions the reaction was successful (Table 1, 4a-k). In all cases 
the product was either prepared in analytically pure form, or, use of a short plug of silica 
was sufficient to remove base-line impurities. Esters, nitriles and halides all successfully 
underwent FP-HM in excellent yields (>90%). The only exceptions were the ortho-Me N-
oxide (4k), which was isolated in 75% yield, and the para-nitro-substituted example (4d, 
66% yield), which presented a slight difficulty because it was poorly soluble in toluene and 
was dissolved in a 1:1 solution of MeCN:PhMe. In this case, full conversion of this substrate 
was not achieved within the usual 10 minutes residence time and 15 min was chosen as a 
compromise; longer reaction times led to substantial photodegradation.  
 
N
O
H N
O
Ar
R
N
O
Ar
R
1 eq. ArNH2, 1.2 t-BuONO
MeCN, 18 h, r.t. to 40 °C
R
2a-b 3a-k 4a-k
hν (>300 nm)
PhMe, 10 min
FPHM
C-H Functionalisation
 
Table 1: Substrate scope of C-H Functionalisation and FP-HM. 
Entry 
Starting N-
Oxide 
C-H coupling 
partner – ArNH2 
C-H 
Functionalisation
a
 
FP-HM
b
 
1  
2a 
4-EtO2CC6H4NH2 
 
39%, 3a 
 
97% (50 mg scale) 
98% (2 g scale) 
4a 
2 2a 4-FC6H4NH2  
31%, 3b  
92%, 4b 
3 2a 4-ClC6H4NH2 
 
45%, 3c  
95%, 4c 
4 2a 4-O2NC6H4NH2 
 
63%, 3d  
66%, 4d
c
 
5 2a PhNH2  
35%, 3e 
 
95%, 4e 
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6 2a MesNH2 
 
Trace, 3f 
N
O
Me
Me
Me  
Not performed, 4f 
7 
 
2b 
4-EtO2CC6H4NH2 
 
38%, 3g  
95%, 4g 
8 2b 4-FC6H4NH2 
 
33%, 3h  
93%, 4h 
9 2b 4-NCC6H4NH2 
 
29%, 3j  
98%, 4j 
10 2b 2-MeC6H4NH2 
 
16%, 3k 
 
75%, 4k 
a) C-H Functionalisation performed as per the general procedure A; b) FP-HM performed as per general 
procedure B; c) Solvent 1:1 MeCN:PhMe, residence time 15 min. 
 
Conclusions 
In conclusion, we have described an efficient method for the synthesis of a small library of 
unusual benzo[1,3]oxazepines in a rapid and cheap manner, starting from commercially-
available quinolines. Molecular diversity was achieved through a very mild C-H 
functionalisation procedure, providing a route for substrate variability. This communication 
has utilised Flow Photochemical Heterocyclic Metamorphosis (FP-HM) to transform the 
well-known quinoline scaffold into benzo[1,3]oxazepines, resulting in changes to the 
molecule’s basicity, geometry, dipole moment, hydrogen-bonding ability and size. 
Heterocyclic metamorphosis represents a different medicinal chemistry paradigm where the 
heterocycle is the function of change rather than a final diversification step. Due to the mild 
nature of FP-HM (10 min of irradiation) it is expected that valuable quinoline-based natural 
products, or late-stage intermediates, could be transformed into the corresponding 
benzo[1,3]oxazepines for additional biological testing, or subsequent additional 
manipulation. Finally, we have demonstrated the true scalability of FP-HM by the successful 
synthesis of 1.9 g of benzo[1,3]oxazepine 4a in 17 hours. The continuous nature of the 
process means that further scale-up can be achieved simply by using multiple cheap 
photoreactors in series.  
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Experimental  
General  
1
H-NMR spectra were recorded on Bruker DPX-400 (400 MHz) or Bruker Nanobay (400 MHz) 
spectrometers using tetramethylsilane (SiMe4, δH = 0.00 ppm); DCCl3 (HCCl3, δH = 7.26 ppm) 
or the central resonance of D3COD (D3COD, δH = 2.50 ppm) as internal reference. 
13
C-NMR 
spectra were recorded on Bruker DPX-400 (101 MHz) or Bruker Nanobay (101 MHz) 
spectrometers using the central resonance of CDCl3 (CDCl3, δC = 77.16 ppm) or the central 
resonance of D3COD (D3COD, δC = 49.00 ppm) as the internal reference. 
19
F-NMR spectra 
were measured relative to CFCl3 δF = 0.00 (external reference). Assignments were made 
using a range of NMR experiments (DEPT135, COSY, HMQC and HMBC). All chemical shifts 
are quoted in parts per million (ppm) down field from tetramethylsilane, measured from the 
centre of the signal except in the case of multiplets of more than one proton, which are 
quoted as a range. Splitting patterns are abbreviated as follows: singlet (s), doublet (d), 
triplet (t), quartet (q), quintet (quin.), multiplet (m), (ap.) apparent, (br) broad and 
combinations thereof. Infrared spectra were recorded on a Perkin-Elmer Spectrum One FT-
IR spectrometer as a thin film. Letters in parentheses refer to relative absorbency of the 
main peak: w, weak, < 40%, m, medium, 41-74% of the main peak, s, strong >75%; and br, 
broad. Accurate mass data was recorded on a V.G. Micromass 70-70F machine under 
chemical ionisation (CI) or under electrospray conditions on a Thermo Scientific LTQ 
Orbitrap XL instrument. PE refers to the fraction of light petroleum ether boiling between 40 
and 60 °C. All reagents were used as obtained from commercial sources, unless otherwise 
stated. Analytical thin layer chromatography (TLC) was performed using pre-coated 
Merck aluminum-backed silica gel plates (Silicagel 60 F254). Visualization was by UV light 
and/or treatment with acidic potassium permanganate, ninhydrin or acidic ammonium 
molybdate(IV). UV-Vis spectrum was collected using a Jenway 6315 Spectrophotometer. The 
emission spectrum from the Exo Terra UVB200 bulb was measured using an Ocean Optics 
Red Tide USB650 fiber optic spectrometer. 
 
General Procedure A – C-H Functionalisation (3a-k) 
The quinoline N-oxide (3 mmol) and aromatic amine (3 mmol) were dissolved in MeCN (10 
mL). tert-Butyl nitrite (3.6 mmol) was added in one portion and the reaction was stirred at 
ambient temperature for 15 mins, before warming to 40 °C overnight (typically 18 h). The 
mixture was dry loaded onto silica gel before purification by flash chromatography (typically 
1:1 EtOAc:PE).  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Flow Photochemical Heterocyclic Metamorphosis C. D. Smith 
7 
General Procedure B – Flow Photochemical Heterocyclic Metamorphosis (FP-HM) (4a-k) 
A solution of substrate in PhMe (typically 50 mg in 30 mL; 5-10 mM) was pumped using a 
Vapourtec E-Scholar peristaltic pump system through a 10 mL reactor (PFA tubing: 1/16” 
OD, 0.5 mm ID) that was wrapped around a 25 W Exo Terra UVB200 lamp, and the solution 
irradiated. In general, the reaction requires a residence time of 6 min (1.67 mL/min); 
however, a residence time of 10 mins (1 mL/min) was typically used to account for 
experimental variabilities. The output from the reactor was concentrated in vacuo and, if 
necessary, was further purified by flash column chromatography (SiO2; 1:2 EtOAc:PE). 
 
Large-Scale Flow Photochemical Heterocyclic Metamorphosis (4a) 
2-(4-(Ethoxycarbonyl)phenyl)quinoline 1-oxide (2 g, 6.8 mmol) was dissolved in PhMe (1 L, 
6.8 mM) and pumped using a Vapourtec E-Scholar peristaltic pump system through a 10 mL 
reactor (PFA tubing: 1/16” OD, 0.5 mm ID) that was wrapped around a 25 W Exo Terra 
UVB200 lamp, and the solution irradiated. A residence time of 10 mins was used; the total 
reaction time was 17 hours. The output from the reactor was concentrated in vacuo to give 
ethyl 4-(benzo[d][1,3]oxazepin-2-yl)benzoate (4a) as a tan solid (1.935 g, 97%). 
 
Batch Photochemical Heterocyclic Metamorphosis (4a) 
Approximately 15 mg of N-oxide 3a was dissolved in PhMe (15 mL) and placed in a Pyrex 
test-tube. The tube was sealed with a septum and placed next to the Exo Terra UVB200 
lamp for 18 h. The reaction was concentrated in vacuo and purified by flash column 
chromatography (SiO2; 1:2 EtOAc:PE) to give ethyl 4-(benzo[d][1,3]oxazepin-2-yl)benzoate 
(4a) a tan solid (11 mg, 73%). 
 
Quinoline N-oxide
15
 (2a) 
Quinoline (10 g, 77 mmol) was dissolved in AcOH (60 mL), then NaBO3·4H2O (15.7 g, 115.5 
mmol) was added portion-wise to the solution over 10 mins. The reaction was heated at 40 
˚C overnight. Most of the AcOH was removed in vacuo and then the reaction partitioned 
with HCCl3 (100 mL) and H2O (300 mL), and the aqueous phase further extracted into HCCl3 
(2×100 mL). The combined organic phases were washed with aq. 2 M NaOH, dried with 
MgSO4, filtered, then concentrated in vacuo to produce a dark brown deliquescent solid 
(6.23 g, 56%). IR (thin film) ν/cm
-1
 = 3397brw, 3063w, 2260w, 1656w, 1569w, 1510w, 
1447w, 1392m, 1226m. 
1
H-NMR (400 MHz, CDCl3): δ/ppm = 8.76 (d, J = 8.5 Hz, 1H), 8.55 (d, J 
= 6.0 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.83 – 7.70 (m, 2H), 7.66 (t, J = 7.5 Hz, 1H), 7.31 (dd, J = 
8.5, 6.0 Hz, 1H). 
13
C-NMR (101 MHz, DMSO-d6): δ/ppm = 140.84 (C), 135.27 (CH), 130.32 (C), 
130.32 (CH), 128.76 (CH), 128.66 (CH), 125.11 (CH), 121.94 (CH), 118.87 (CH). HRMS: (ESI
+
) 
[M+H]
+
 calculated for C9H8ON = 146.0606, found = 146.0600. 
 
4-Methylquinoline 1-oxide
16
 (2b) 
4-Methylquinoline (5.4 g, 38 mmol) was dissolved in AcOH (40 mL), then NaBO3·4H2O (8 g, 
59 mmol) was added portion-wise to the solution over 10 mins. The reaction was heated at 
40 ˚C overnight. Most of the AcOH was removed in vacuo, then the reaction partitioned with 
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HCCl3 (50 mL) and H2O (150 mL), and the aqueous phase further extracted into HCCl3 (2×50 
mL). The combined organic phases were washed with aq. 2 M NaOH, dried with MgSO4, 
filtered, then concentrated in vacuo to produce an off-white deliquescent solid (2.7 g, 45%). 
IR (thin film) ν/cm
-1
 = 3283br w, 1571m, 1514w, 1394s, 1313m, 1277m, 1206m, 1145s, 
1057m, 1040w, 969w, 826w, 791s, 702m. 
1
H-NMR (400 MHz, D3COD): δ/ppm = 8.67 (d, J = 
8.5 Hz, 1H), 8.58 (d, J = 6.0 Hz, 1H), 8.20 (d, J = 8.5 Hz, 1H), 7.93 (t, J = 8.0 Hz, 1H), 7.82 (t, J = 
7.5 Hz, 1H), 7.41 (d, J = 6.0 Hz, 1H), 2.75 (s, 3H). 
13
C-NMR (101 MHz, D3COD): δ/ppm = 
141.20 (C), 141.06 (C), 137.66 (CH), 132.49 (CH), 131.19 (C), 130.23 (CH), 126.55 (CH), 
122.88 (CH), 120.26 (CH), 18.49 (CH3). HRMS (ESI
+
) [M+H]
+
 calculated for C10H10ON = 
160.0757, found = 160.0753. 
 
2-(4-(Ethoxycarbonyl)phenyl)quinoline 1-oxide
13b
 (3a) 
Off-white solid 341 mg, 39%. IR (thin film) ν/cm
-1
 = 1709s, 1561w, 1343m, 1273s, 1206w, 
1102m, 1027w, 892w, 820m, 763m, 737m, 699w. 
1
H-NMR (400 MHz, CDCl3): δ/ppm = 8.82 
(d, J = 8.5 Hz, 1H), 8.17 (app. d, J = 7.5 Hz, 2H), 8.05 (app. d, J = 7.5 Hz, 2H), 7.87 (m, 1H), 
7.83 – 7.73 (m, 2H), 7.65 (t, J = 7.0 Hz, 1H), 7.50 (d, J = 8.5 Hz, 1H), 4.41 (q, J = 7.0 Hz, 2H), 
1.42 (t, J = 7.0 Hz, 3H). 
13
C-NMR (101 MHz, CDCl3): δ/ppm = 166.04 (CO), 143.99 (C), 142.20 
(C), 137.66 (C), 131.08 (C), 130.76 (CH), 129.74 (C), 129.57 (CH), 129.38 (CH), 128.75 (CH), 
128.08 (CH), 125.48 (CH), 123.02 (CH), 120.14 (CH), 61.17 (CH2), 14.32 (CH3). HRMS (ESI
+
) 
[M+H]
+
 calculated for C18H16O3N = 294.1125, found = 294.1121. λmax (PhMe) = 346 nm, ε = 
14.3 M
-1
cm
-1
. 
 
2-(4-Fluorophenyl)quinoline 1-oxide
17
 (3b) 
Off-white solid 221 mg, 31%. IR (thin film) ν/cm
-1
 = 1600m, 1563m, 1501s, 1453w, 1326s, 
1299m, 1232s, 1205w, 1162m, 1149w, 1096w, 1060w, 1017w, 889m, 805s, 802s, 769m, 
737s, 606m. 
1
H-NMR (400 MHz, CDCl3): δ/ppm =
 
8.80 (d, J = 6.5 Hz, 1H), 8.04 – 7.93 (m, 2H), 
7.82 (d, J = 7.5 Hz, 1H), 7.79 – 7.67 (m, 2H), 7.61 (d, J = 7.0 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 
7.22 – 7.08 (m, 2H). 
13
C-NMR (101 MHz, CDCl3): δ/ppm = 163.17 (d, J = 250.5 Hz, CF), 144.14 
(C), 142.13 (C), 131.81 (d, J = 8.5 Hz, CH), 130.76 (CH), 129.50 (C), 129.37 (d, J = 3.0 Hz, C), 
128.51 (CH), 128.06 (CH), 125.75 (CH), 122.99 (CH), 120.07 (CH), 115.34 (d, J = 21.5 Hz, CH). 
19
F-NMR (376 MHz, CDCl3): δ/ppm = -110.40. HRMS (ESI
+
) [M+H]
+
 calculated for C15H11ONF = 
240.0819, found = 240.0825. 
 
2-(4-Chlorophenyl)quinoline 1-oxide
17
 (3c) 
Off-white solid 344 mg, 45%. IR (thin film) ν/cm
-1
 = 1688w, 1598w, 1561 w, 1487m, 1336s, 
1324s, 1298m, 1278m, 1149m, 1093s, 1015m, 890m, 821s, 769m, 729m. 
1
H-NMR (400 MHz, 
CDCl3): δ/ppm 8.82 (d, J = 8.5 Hz, 1H), 7.94 (app. d, J = 8.5 Hz, 2H), 7.86 (d, J = 8.0 Hz, 1H), 
7.82 – 7.72 (m, 2H), 7.65 (t, J = 7.5 Hz, 1H), 7.50 – 7.46 (m, 3H). 
13
C-NMR (101 MHz, CDCl3): 
δ/ppm = 143.93 (C), 142.17 (C), 135.55 (C), 131.76 (C), 131.01 (CH), 130.81 (CH), 129.61 (C), 
128.65 (CH), 128.54 (CH), 128.07 (CH), 125.66 (CH), 122.90 (CH), 120.13 (CH). HRMS (ESI
+
) 
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[M+H]
+
 calculated for C15H11ON
35
Cl = 256.0524, found = 256.0525; C15H11ON
37
Cl = 258.0494, 
found = 258.0496. 
 
2-(4-Nitrophenyl)quinoline 1-oxide
17
 (3d) 
Yellow solid 502 mg, 63%. IR (thin film) ν/cm
-1
 = 1591m, 1511s, 1324s, 1247w, 1103w, 892w, 
843m, 810s, 755s, 734s, 694m. 
1
H-NMR (400 MHz, CDCl3): δ/ppm = 8.82 (d, J = 8.5 Hz, 1H), 
8.35 (app. d, J = 8.0 Hz, 2H), 8.18 (app. d, J = 8.0 Hz, 2H), 7.92 (d, J = 8.0 Hz, 1H), 7.84 (t, J = 
7.0 Hz, 2H), 7.71 (t, J = 7.5 Hz, 1H), 7.53 (d, J = 8.5 Hz, 1H). 
13
C-NMR (101 MHz, CDCl3): 
δ/ppm = 147.95 (C), 142.77 (C), 142.30 (C), 139.70 (C), 131.11 (CH), 130.71 (CH), 130.00 (C), 
129.22 (CH), 128.21 (CH), 125.70 (CH), 123.44 (CH), 122.65 (CH), 120.19 (CH). HRMS (ESI
+
) 
[M+H]
+
 calculated for C15H11O3N2 = 267.0764, found = 267.0767. 
 
2-Phenylquinoline 1-oxide
18
 (3e) 
Off-white solid 232 mg, 35%. IR (thin film) ν/cm
-1
 = 1560m, 1491m, 1449w, 1348m, 1323m, 
1283w, 1203w, 1133m, 1109m, 1061w, 888m, 761s, 733s, 695s, 609m, 567m, 540w. 
1
H-
NMR (400 MHz, CDCl3): δ/ppm = 8.86 (d, J = 8.5 Hz, 1H), 7.97 (d, J = 7.0 Hz, 1H), 7.88 (d, J = 
8.0 Hz, 1H), 7.83 – 7.74 (m, 2H), 7.67 (m, 1H), 7.56 – 7.44 (m, 5H). 
13
C-NMR (101 MHz, 
CDCl3): δ/ppm = 145.24 (C), 142.40 (C), 133.60 (C), 130.77 (CH), 129.73 (CH), 129.70 (CH), 
128.59 (CH), 128.45 (CH), 128.38 (C), 128.11 (CH), 125.52 (CH), 123.47 (CH), 120.43 (CH). 
HRMS (ESI
+
) [M+H]
+
 calculated for C15H12ON = 222.0913, found = 222.0912. 
 
2-(4-(Ethoxycarbonyl)phenyl)-4-methylquinoline 1-oxide – novel (3g) 
Off-white solid 349 mg, 38%. IR (thin film) ν/cm
-1
 = 2980w, 1714s, 1607w, 1560w, 1385w, 
1366w, 1339m, 1291s, 1210w, 1104m, 1020w, 765m. 
1
H-NMR (400 MHz, CDCl3): δ/ppm =
 
8.91 (d, J = 7.0 Hz, 1H), 8.18 (app. d, J = 7.5 Hz, 2H), 8.06 (app. d, J = 7.5 Hz, 2H), 7.99 (d, J = 
8.0 Hz, 1H), 7.82 (m, 1H), 7.70 (t, J = 7.5 Hz, 1H), 7.35 (br s, 1H), 4.41 (q, J = 7.0 Hz, 2H), 2.71 
(s, 3H), 1.43 (t, J = 7.0 Hz, 3H). 
13
C-NMR (101 MHz, CDCl3): δ/ppm = 166.13 (CO), 141.72 (C), 
137.74 (C), 134.00 (C), 131.04 (C), 130.50 (CH), 129.64 (CH), 129.49 (C), 129.37 (CH), 129.27 
(C), 128.51 (CH), 124.69 (CH), 123.4 (CH). 120.74 (CH), 61.18 (CH2), 18.36 (CH3), 14.33 (CH3). 
HRMS (ESI
+
) [M+H]
+
 calculated for C19H18O3N = 308.1281, found = 308.1282. 
 
2-(4-Fluorophenyl)-4-methylquinoline 1-oxide – novel (3h) 
Pale brown solid 253 mg, 33%. IR (thin film) ν/cm
-1
 = 1603m, 1510s, 1504s, 1398w, 1384w, 
1338s, 1234s, 1208m, 1160m, 1150m, 1061w, 871w, 838s, 811w, 795w, 761m. 
1
H-NMR (400 
MHz, CDCl3): δ/ppm =
 
8.90 (d, J = 8.5 Hz, 1H), 8.10-7.80 (m, 3H), 7.80 (m, 1H), 7.68 (m, 1H), 
7.33 (m, 1H), 7.20 (m, 2H), 2.69 (s, 3H). 
13
C-NMR (101 MHz, CDCl3): δ/ppm = 163.18 (d, J = 
250.5 Hz, CF), 143.49 (C), 141.67 (C), 134.02 (C), 131.82 (d, J = 8.5 Hz, CH), 130.46 (CH), 
129.48 (d, J = 3.5 Hz, C), 129.08 (C), 128.29 (CH), 124.63 (CH), 123.48 (CH), 120.73 (CH), 
115.33 (d, J = 21.5 Hz, CH), 18.37 (CH3). 
19
F-NMR (376 MHz, CDCl3): δ/ppm =
 
-110.66. HRMS 
(ESI
+
) [M+H]
+
 calculated for C16H13ONF = 254.0976, found = 254.0977. 
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2-(4-Cyanophenyl)-4-methylquinoline 1-oxide – novel (3j) 
Tan solid 226 mg, 29%. IR (thin film) ν/cm
-1
 = 3054w, 2226s, 1605m, 1565w, 1501m, 1383s, 
1369w, 1339s, 1306w, 1234w, 1209m, 1151m, 869w, 840m, 759s, 731m, 559s. 
1
H-NMR (400 
MHz, CDCl3): δ/ppm = 8.87 (d, J = 8.5 Hz, 1H), 8.10 (app. d, J = 8.0 Hz, 2H), 8.01 (d, J = 8.5 Hz, 
1H), 7.86 – 7.76 (m, 3H), 7.72 (t, J = 7.5 Hz, 1H), 7.32 (s, 1H), 2.71 (s, 3H, CH3). 
13
C-NMR (101 
MHz, CDCl3): δ/ppm = 145.48 (C), 141.80 (C), 138.10 (C), 134.28 (C), 132.11 (CH), 130.83 
(CH), 130.48 (CH), 129.58 (C), 128.98 (CH), 124.90 (CH), 123.15 (CH), 120.86 (CH), 118.67 (C), 
112.99 (C), 18.56 (CH3). HRMS (ESI
+
) [M+H]
+
 calculated for C17H13ON2 = 261.1022, found = 
261.1020. 
 
4-Methyl-2-(o-tolyl)quinoline 1-oxide – novel (3k) 
Dark brown amorphous solid 120 mg, 16%. IR (thin film) ν/cm
-1
 = 2924w, 1600w, 1561w, 
1494w, 1457w, 1387m, 1368w, 1338s, 1282w, 1234m, 1209m, 1150m, 1060w, 910w, 871w, 
758s, 729s. 
1
H-NMR (400 MHz, CDCl3): δ/ppm = 8.90 (d, J = 8.5 Hz, 1H), 8.01 (d, J = 8.5 Hz, 
1H), 7.80 (t, J = 7.5 Hz, 1H), 7.70 (t, J = 7.5 Hz, 1H), 7.41 – 7.28 (m, 4H), 7.20 (s, 1H), 2.69 (s, 
3H), 2.26 (s, 3H). 
13
C-NMR (101 MHz, CDCl3): δ/ppm = 146.34 (C), 141.53 (C), 137.77 (C), 
134.00 (C), 133.51 (C), 130.34 (CH), 130.20 (CH), 129.44 (C), 129.36 (CH), 129.17 (CH), 
128.35 (CH), 125.97 (CH), 124.79 (CH), 124.32 (CH), 120.91 (CH), 19.79 (CH3), 18.42 (CH3). 
HRMS (ESI
+
) [M+H]
+
 calculated for C17H16ON = 250.1226, found = 250.1221. 
 
Flow Photochemical Heterocyclic Metamorphosis 
 
Ethyl 4-(benzo[d][1,3]oxazepin-2-yl)benzoate – novel (4a) 
Tan solid 49 mg, 98%; large scale 1.935 g, 97%. 
IR (thin film) ν/cm
-1
 = 1715s, 1661w, 1596w, 1407w, 1366s, 1207m, 1103m, 1034m, 761m. 
1
H-NMR (400 MHz, CDCl3): δ/ppm = 8.16 (app. d, J = 8.5 Hz, 2H), 8.09 (app. d, J = 8.5 Hz, 2H), 
7.30 – 7.24 (m, 2H), 7.13 (m, 1H), 7.08 (d, J = 7.5 Hz, 1H), 6.28 (d, J = 5.5 Hz, 1H), 6.00 (d, J = 
5.5 Hz, 1H), 4.41 (q, J = 7.0 Hz, 2H), 1.42 (t, J = 7.0 Hz, 3H). 
13
C-NMR (101 MHz, CDCl3): 
δ/ppm =166.06 (CO), 152.75 (C), 144.82 (C), 144.50 (CH), 136.74 (C), 132.80 (C), 130.07 (C), 
129.53 (CH), 129.26 (CH), 129.06 (CH), 128.64 (CH), 128.25 (CH), 126.18 (CH), 117.50 (CH), 
61.29 (CH2), 14.32 (CH3). HRMS (ESI
+
) [M+H]
+
 calculated for C18H16O3N = 294.1125, found = 
294.1128. 
 
2-(4-Fluorophenyl)benzo[d][1,3]oxazepine – novel (4b) 
Tan solid 46 mg, 92%. IR (thin film) ν/cm
-1
 = 1662m, 1634m, 1595m, 1504s, 1484w, 1444w, 
1261m, 1207s, 1193s, 1151m, 1113m, 1098m, 843w, 761s. 
1
H-NMR (400 MHz, CDCl3): 
δ/ppm = 8.12 (app. dd, J = 8.5, 5.5 Hz, 2H), 7.27 – 7.23 (m, 2H), 7.15 – 7.06 (m, 4H), 6.28 (d, J 
= 5.5 Hz, 1H), 6.00 (d, J = 5.5 Hz, 1H). 
13
C-NMR (101 MHz, CDCl3): δ/ppm = 165.06 (d, J = 
252.5 Hz, CF), 152.97 (C), 145.17 (C), 144.63 (CH), 131.62 (d, J = 9.0 Hz, CH), 130.05 (C), 
129.34 (CH), 129.11 (d, J = 3.0 Hz, C), (C), 128.50 (CH), 128.32 (CH), 125.89 (CH), 117.71 (CH), 
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115.60 (d, J = 22.0 Hz, CH). 
19
F-NMR (376 MHz, CDCl3): δ/ppm = -108.1. HRMS (ESI
+
) [M+H]
+
 
calculated for C15H11ONF = 240.0819, found = 240.0827. 
 
2-(4-Chlorophenyl)benzo[d][1,3]oxazepine – reported but with no NMR
9c
 (4c) 
Off-white solid 47 mg, 95%. IR (thin film) ν/cm
-1
 = 1661m, 1633w, 1592s, 1571w, 1488w, 
1445w, 1401w, 1285m, 1259m, 1207w, 1183w, 1113, 1090s, 1032w, 761s, 523w. 
1
H-NMR 
(400 MHz, CDCl3): δ/ppm = 8.04 (app. d, J = 8.5 Hz, 2H), 7.40 (app. d, J = 8.5 Hz, 2H), 7.28 – 
7.22 (m, 2H), 7.16 – 7.04 (m, 2H), 6.27 (d, J = 5.5 Hz, 1H), 5.99 (d, J = 5.5 Hz, 1H). 
13
C-NMR 
(101 MHz, CDCl3): δ/ppm = 145.04 (C), 144.61 (CH), 137.87 (C), 131.43 (C), 130.65 (CH), 
130.10 (C), 129.36 (CH), 129.18 (CH), 128.80 (C), 128.58 (CH), 128.35 (CH), 126.05 (CH), 
117.68 (CH). HRMS (ESI
+
) [M+H]
+
 calculated for C15H11NO
35
Cl = 256.0524, found = 256.0530; 
C15H11NO
37
Cl = 258.0494, found = 258.0501. 
 
2-(4-Nitrophenyl)benzo[d][1,3]oxazepine – novel (4d) 
Due to solubility difficulties this transformation required a 1:1 MeCN:PhMe solvent system. 
A residence time of 15 min was used as a compromise between conversion and 
photodecomposition. Orange solid 33 mg, 66%. IR (thin film) ν/cm
-1
 = 1660w, 1598m, 1519s, 
1482w, 1360s, 1261w, 1208w, 111w, 1036w, 1012w, 854m, 756m, 712w. 
1
H-NMR (400 
MHz, CDCl3): δ/ppm = 8.26 (app. s, 4H), 7.29 – 7.25 (m, 2H), 7.16 (m, 1H), 7.08 (d, J = 7.5 Hz, 
1H), 6.26 (d, J = 6.0 Hz, 1H), 5.98 (d, J = 6.0 Hz, 1H). 
13
C-NMR (101 MHz, CDCl3): δ/ppm = 
151.54 (C), 149.58 (C), 144.53 (C), 144.40 (CH), 138.77 (C), 130.21 (C), 130.14 (CH), 129.54 
(CH), 129.06 (CH), 128.63 (CH), 126.90 (CH), 123.68 (CH), 117.57 (CH). HRMS (ESI
+
) [M+H]
+
 
calculated for C15H11O3N2 = 267.0764, found = 267.0767. 
 
2-Phenylbenzo[d][1,3]oxazepine
11,19
 (4e) 
Off-white solid 46 mg, 95%. IR (thin film) ν/cm
-1
 = 3059w, 1651s, 1631m, 1448w, 1208m, 
1197m, 1113w, 1037w, 1020w, 758m, 691w. 
1
H-NMR (400 MHz, CDCl3): δ/ppm = 8.14 – 
8.10 (m, 2H), 7.51 – 7.39 (m, 3H), 7.31 – 7.23 (m, 2H), 7.15 – 7.06 (m, 2H), 6.30 (d, J = 5.5 Hz, 
1H), 6.02 (d, J = 5.5 Hz, 1H). 
13
C-NMR (101 MHz, CDCl3): δ/ppm = 153.95 (C), 145.31 (C), 
144.79 (CH), 132.87 (C), 131.64 (CH), 130.12 (C), 129.35 (CH), 129.28 (CH), 128.53 (CH), 
128.49 (CH), 128.22 (CH), 125.79 (CH), 117.76 (CH). HRMS (ESI
+
) [M+H]
+
 calculated for 
C15H12ON = 222.0913, found = 22.0916. 
 
Ethyl 4-(5-methylbenzo[d][1,3]oxazepin-2-yl)benzoate – novel (4g) 
Off-white solid 47 mg, 95%. IR (thin film) ν/cm
-1
 = 1716s, 1655w, 1634w, 1367w, 1301s, 
1202w, 110s, 1011m, 761w. 
1
H-NMR (400 MHz, CDCl3): δ/ppm = 8.19 (app. d, J = 8.5 Hz, 2H), 
8.10 (app. d, J = 8.5 Hz, 2H), 7.40 (d, J = 8.0 Hz, 1H), 7.36 – 7.30 (m, 2H), 7.22 (m, 1H), 6.33 
(q, J = 1.0 Hz, 1H), 4.41 (q, J = 7.0 Hz, 2H), 2.02 (d, J = 1.0 Hz, 3H), 1.42 (t, J = 7.0 Hz, 3H). 
13
C-
NMR (101 MHz, CDCl3): δ/ppm = 166.19 (CO), 154.62 (C), 144.81 (C), 140.66 (CH), 136.58 
(C), 132.95 (C), 132.12 (C), 129.73 (CH), 129.07 (CH), 128.16 (CH), 128.00, (CH) 126.70 (CH), 
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125.69 (CH), 125.28 (C), 61.41 (CH2), 15.35 (CH3), 14.43 (CH3). HRMS (ESI
+
) [M+H]
+
 calculated 
for C19H18O3N = 308.1281, found = 308.1282. 
 
2-(4-Fluorophenyl)-5-methylbenzo[d][1,3]oxazepine – novel (4h) 
Off-white solid 47 mg, 98%. IR (thin film) ν/cm
-1
 = 1655m, 1597s, 1503s, 1480m, 1441w, 
1410w, 1284m, 1258m, 1225m, 1202m, 1153m, 1095m, 1010w, 841w, 763m. 
1
H-NMR (400 
MHz, CDCl3): δ/ppm = 8.19 – 8.10 (m, 2H), 7.39 (d, J = 8.5 Hz, 1H), 7.35 – 7.28 (m, 2H), 7.20 
(m, 1H), 7.17 – 7.08 (m, 2H), 6.33 (s, 1H), 2.03 (s, 3H). 
13
C-NMR (101 MHz, CDCl3): δ/ppm = 
164.96 (d, J = 252.5 Hz, CF), 154.61 (C), 144.90 (C), 140.59 (CH), 131.90 (C), 131.39 (d, J = 9.0 
Hz, CH), 128.75 (C), 128.01 (CH), 127.70 (CH), 126.56 (CH), 125.21 (CH), 125.17 (C), 115.58 
(d, J = 22.0 Hz, CH), 15.26 (s, CH3). 
19
F-NMR (376 MHz, CDCl3): δ/ppm = 108.0. HRMS (ESI
+
) 
[M+H]
+
 calculated for C16H13ONF = 254.0976, found = 254.0982. 
 
4-(5-Methylbenzo[d][1,3]oxazepin-2-yl)benzonitrile – novel (4j) 
Off-white solid 49 mg, 98%. IR (thin film) ν/cm
-1
 = 3063w, 2228m, 1659m, 1634w, 1596w, 
1564w, 1500w, 1483w, 1441w, 1407w, 1283w, 1259m, 1203s, 1093s, 1073m, 1026w, 1012s, 
863w, 843w, 762s. 
1
H-NMR (400 MHz, CDCl3): δ/ppm = 8.23 (app. d, J = 8.5 Hz, 2H), 7.73 
(app. d, J = 8.5 Hz, 2H), 7.42 – 7.13 (m, 4H), 6.30 (s, 1H), 2.03 (s, 3H). 
13
C-NMR (101 MHz, 
CDCl3): δ/ppm = 153.61 (C), 144.49 (C), 140.46 (CH), 136.82 (C), 132.36 (CH), 132.11 (C), 
129.59 (CH), 128.34 (CH), 128.13 (CH), 126.82 (CH), 126.08 (CH), 125.39 (C), 118.55 (C), 
114.75 (C), 15.40 (CH3). HRMS (ESI
+
) [M+H]
+
 calculated for C17H13ON2 = 261.1022, found = 
261.1026. 
 
5-Methyl-2-(o-tolyl)benzo[d][1,3]oxazepine – novel (4k) 
Off-white solid 38 mg, 75%. IR (thin film) ν/cm
-1
 = 2956w, 2923w, 1652m, 1633w, 1597w, 
1570w, 1483m, 1454w, 1440w, 1254m, 1193s, 1095s, 1071w, 1002s, 981w, 758s, 726m. 
1
H-
NMR (400 MHz, CDCl3): δ/ppm = 7.92 (d, J = 7.0 Hz, 1H), 7.43 – 7.24 (m, 6H), 7.21 (m, 1H), 
6.33 (q, J = 1.0 Hz, 1H), 2.69 (s, 3H), 2.04 (d, J = 1.0 Hz, 3H). 
13
C-NMR (101 MHz, CDCl3): 
δ/ppm = 156.12 (C), 145.21 (C), 140.67 (CH), 139.83 (C), 134.43 (C), 132.03 (C), 131.82 (CH), 
130.78 (CH), 130.59 (CH), 127.99 (CH), 127.86 (CH), 126.62 (CH), 125.89 (CH), 125.26 (CH), 
125.04 (C), 22.75 (CH3), 15.34 (CH3). HRMS (ESI
+
) [M+H]
+
 calculated for C17H16ON = 250.1226, 
found = 250.1227. 
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